AcroMeta Group Limited Announces Receipt of SGX Listing and Quotation Notice for New Shares Under ESOS 2026

Key Highlights

• SGX Approval: AcroMeta Group Limited has received the Listing and Quotation Notice (LQN) from the Singapore Exchange Securities Trading Limited (SGX-ST) for the listing and quotation of new ordinary shares to be issued under its Employee Share Option Scheme 2026 (ESOS 2026).
• Shareholder Approval: The ESOS 2026 was approved by shareholders at the Annual General Meeting held on 23 January 2026.
• Compliance: The listing and quotation of new shares are subject to compliance with the SGX-ST’s listing requirements.
• Announcement Date: The company received the LQN on 19 March 2026 and made the official announcement on 20 March 2026.
• Ongoing Disclosure: AcroMeta will provide further announcements regarding any material developments related to ESOS 2026, including the grant of share awards or options and the issuance/allotment of new shares.

Important Information for Shareholders

• Potential Price Sensitivity: The adoption and implementation of ESOS 2026 may impact the company’s share capital and, consequently, share value. Issuance of new shares through employee options could lead to dilution for existing shareholders, depending on the volume and timing of share issuance.
• No Endorsement by SGX: Shareholders should note that the LQN from SGX-ST is not an endorsement of the merits of ESOS 2026, the new shares, or the company and its subsidiaries.
• Future Announcements: Investors should stay alert for further updates from the company regarding the actual granting of share awards/options and the issuance/allotment of new shares, as these events may be significant and potentially price-sensitive.
• Corporate Governance: The announcement has been reviewed by AcroMeta’s Sponsor, W Capital Markets Pte. Ltd., but not examined or approved by SGX-ST, which assumes no responsibility for its contents.
• Contact Information: For queries, the sponsor contact is Mr. Brian Ching at 65 Chulia Street, #43-01, OCBC Centre, Singapore 049513, telephone (65) 6513 3525.

Investor Implications

The approval and listing of new shares under the ESOS 2026 represent a significant corporate event for AcroMeta Group Limited. Employee share option schemes are designed to align staff incentives with shareholder interests, potentially improving performance and retention. However, any substantial issuance of new shares under the scheme may dilute existing shareholdings, which can affect the company’s share price.

Investors should closely monitor the company’s future announcements related to ESOS 2026, particularly regarding the number of options granted, the terms of these options, and the actual issuance of new shares. These developments could be material to the company’s valuation and trading dynamics.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or an endorsement of AcroMeta Group Limited, its securities, or its corporate actions. All investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The Singapore Exchange Securities Trading Limited (SGX-ST) does not assume responsibility for the contents of this article.

View AcroMeta Historical chart here